PIMT Inhibitors refer to a class of chemical compounds designed to specifically target and modulate the activity of the enzyme Protein L-Isoaspartyl Methyltransferase (PIMT). PIMT is a critical enzyme involved in the repair of damaged proteins, particularly those containing abnormal isoaspartyl residues. These isoaspartyl residues can arise from spontaneous protein deamidation or damage due to chemical and physical stress. PIMT catalyzes the conversion of these abnormal isoaspartyl residues back into their normal forms, thus preserving the structural and functional integrity of proteins. PIMT inhibitors, as the name suggests, are compounds that interfere with the enzymatic activity of PIMT, potentially leading to the accumulation of damaged proteins within cells.
The mechanism of action of PIMT inhibitors typically involves binding to the active site of the PIMT enzyme or disrupting its essential cofactors or coenzymes. By inhibiting PIMT, these compounds inhibit the enzyme from efficiently repairing isoaspartyl residues in proteins, which can have downstream consequences on cellular function. The development of PIMT inhibitors is of interest in the field of molecular biology and protein chemistry, as they can serve as valuable tools for studying the consequences of isoaspartyl residue accumulation in various cellular processes. Additionally, understanding the role of PIMT and its regulation through inhibitors may offer insights into the mechanisms underlying protein misfolding and the development of age-related diseases like neurodegenerative disorders. These inhibitors hold significant promise in advancing our understanding of protein homeostasis and the broader implications of protein damage within biological systems.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Inhibits the BCR-ABL kinase, blocking cell signaling in chronic myeloid leukemia. | ||||||
Ritonavir | 155213-67-5 | sc-208310 | 10 mg | $124.00 | 7 | |
Acts as a protease inhibitor, preventing viral replication in HIV-infected cells. | ||||||
Tamoxifen | 10540-29-1 | sc-208414 | 2.5 g | $272.00 | 18 | |
Competes with estrogen for binding to estrogen receptors. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Targets the EGFR kinase, disrupting signaling pathways in non-small cell lung cancer. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Inhibits multiple kinases, including RAF and VEGFR. | ||||||
Omeprazole | 73590-58-6 | sc-202265 | 50 mg | $67.00 | 4 | |
Proton pump inhibitor that reduces gastric acid production, used for acid-related disorders. | ||||||
Rosiglitazone | 122320-73-4 | sc-202795 sc-202795A sc-202795C sc-202795D sc-202795B | 25 mg 100 mg 500 mg 1 g 5 g | $120.00 $326.00 $634.00 $947.00 $1259.00 | 38 | |
Activates PPARγ. | ||||||
Allopurinol | 315-30-0 | sc-207272 | 25 g | $131.00 | ||
Blocks xanthine oxidase to reduce uric acid production. | ||||||
Cimetidine | 51481-61-9 | sc-202996 sc-202996A | 5 g 10 g | $62.00 $86.00 | 1 | |
Histamine H2 receptor antagonist, decreasing gastric acid secretion for ulcers and GERD. | ||||||
Donepezil | 120014-06-4 | sc-279006 | 10 mg | $74.00 | 3 | |
Acetylcholinesterase inhibitor. | ||||||